Alumis (ALMS) Competitors $4.51 -0.10 (-2.17%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$4.46 -0.04 (-1.00%) As of 10/24/2025 07:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ALMS vs. STOK, VCEL, RCUS, TLRY, TWST, BHVN, IMCR, ABCL, PAHC, and JANXShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Stoke Therapeutics (STOK), Vericel (VCEL), Arcus Biosciences (RCUS), Tilray Brands (TLRY), Twist Bioscience (TWST), Biohaven (BHVN), Immunocore (IMCR), AbCellera Biologics (ABCL), Phibro Animal Health (PAHC), and Janux Therapeutics (JANX). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Stoke Therapeutics Vericel Arcus Biosciences Tilray Brands Twist Bioscience Biohaven Immunocore AbCellera Biologics Phibro Animal Health Janux Therapeutics Alumis (NASDAQ:ALMS) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, institutional ownership, media sentiment, profitability, dividends, analyst recommendations and valuation. Which has more risk and volatility, ALMS or STOK? Alumis has a beta of -1.47, suggesting that its stock price is 247% less volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Is ALMS or STOK more profitable? Stoke Therapeutics has a net margin of 26.25% compared to Alumis' net margin of 0.00%. Stoke Therapeutics' return on equity of 18.32% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets AlumisN/A -119.15% -92.50% Stoke Therapeutics 26.25%18.32%15.48% Which has preferable earnings and valuation, ALMS or STOK? Stoke Therapeutics has higher revenue and earnings than Alumis. Alumis is trading at a lower price-to-earnings ratio than Stoke Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlumis$20.06M23.40-$294.23M-$4.72-0.96Stoke Therapeutics$199.89M8.85-$88.98M$0.8537.98 Do analysts rate ALMS or STOK? Alumis currently has a consensus target price of $20.17, suggesting a potential upside of 347.15%. Stoke Therapeutics has a consensus target price of $30.83, suggesting a potential downside of 4.48%. Given Alumis' stronger consensus rating and higher probable upside, equities research analysts clearly believe Alumis is more favorable than Stoke Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alumis 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89Stoke Therapeutics 1 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.88 Does the media favor ALMS or STOK? In the previous week, Stoke Therapeutics had 5 more articles in the media than Alumis. MarketBeat recorded 9 mentions for Stoke Therapeutics and 4 mentions for Alumis. Alumis' average media sentiment score of 1.10 beat Stoke Therapeutics' score of 0.89 indicating that Alumis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alumis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Stoke Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryStoke Therapeutics beats Alumis on 9 of the 14 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$469.33M$3.42B$6.24B$10.69BDividend YieldN/A2.27%5.72%4.81%P/E Ratio-0.9628.2931.4730.88Price / Sales23.40467.43564.64176.26Price / CashN/A46.1437.0861.44Price / Book0.8210.4012.056.61Net Income-$294.23M-$52.83M$3.33B$277.10M7 Day Performance0.45%2.10%1.93%2.56%1 Month Performance13.03%12.33%7.77%3.77%1 Year Performance-62.10%14.14%56.40%33.01% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis3.2689 of 5 stars$4.51-2.2%$20.17+347.2%-62.3%$469.33M$20.06M-0.96N/ANews CoveragePositive NewsAnalyst ForecastSTOKStoke Therapeutics3.2784 of 5 stars$33.53-1.9%$30.83-8.0%+167.9%$1.84B$36.56M39.45100Analyst ForecastGap UpVCELVericel3.4507 of 5 stars$35.32+1.6%$58.40+65.3%-15.3%$1.78B$237.22M294.36300Analyst ForecastRCUSArcus Biosciences2.7657 of 5 stars$16.49-0.7%$26.78+62.4%-2.9%$1.76B$258M-5.20500Analyst ForecastTLRYTilray Brands3.2321 of 5 stars$1.56+1.3%$2.00+28.2%-9.1%$1.72B$821.31M-0.692,842Analyst ForecastTWSTTwist Bioscience4.0023 of 5 stars$28.16-8.4%$48.56+72.4%-15.2%$1.70B$312.97M-19.42990Analyst ForecastGap UpBHVNBiohaven3.4108 of 5 stars$16.00-2.9%$48.85+205.3%-68.3%$1.69BN/A-2.09239News CoverageAnalyst ForecastIMCRImmunocore2.6796 of 5 stars$33.56+0.1%$56.89+69.5%+1.8%$1.69B$310.20M-83.90320News CoverageAnalyst ForecastABCLAbCellera Biologics2.4212 of 5 stars$5.59-4.3%$8.00+43.1%+109.6%$1.67B$28.83M-10.16500Analyst ForecastGap UpPAHCPhibro Animal Health3.8265 of 5 stars$39.72+3.0%$28.40-28.5%+80.8%$1.61B$1.30B33.662,475News CoverageInsider TradeJANXJanux Therapeutics1.9722 of 5 stars$26.76-1.6%$78.31+192.6%-53.3%$1.61B$10.59M-14.8730News CoverageAnalyst Forecast Related Companies and Tools Related Companies STOK Alternatives VCEL Alternatives RCUS Alternatives TLRY Alternatives TWST Alternatives BHVN Alternatives IMCR Alternatives ABCL Alternatives PAHC Alternatives JANX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored$4,200 gold is nice ... but here’s what most gold bugs are missingGold just surged past $4,200, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ALMS Stock Alerts